The IGLC2 antibody targets the immunoglobulin lambda constant 2 (IGLC2) protein, a component of the lambda light chain in immunoglobulins (antibodies). Immunoglobulins consist of two heavy chains and two light chains (kappa or lambda), with lambda chains encoded by gene clusters including IGLC2. This protein contributes to the constant region of antibodies, influencing their structural stability and effector functions, such as complement activation and receptor binding.
IGLC2 antibodies are primarily used in research to study B-cell development, antibody diversity, and pathologies involving lambda light chains, such as B-cell malignancies (e.g., multiple myeloma) or autoimmune disorders. They help detect lambda chain expression in tissues or serum, aiding in diagnostics and subtyping of monoclonal gammopathies.
Commercial IGLC2 antibodies are typically monoclonal or polyclonal, validated for techniques like immunohistochemistry, flow cytometry, or Western blot. Challenges include cross-reactivity with homologous lambda chain isoforms (e.g., IGLC1. IGLC3), necessitating careful validation. Recent studies also explore IGLC2's role in immune microenvironment regulation, highlighting its potential as a therapeutic target or biomarker. Overall, IGLC2 antibodies are vital tools for understanding humoral immunity and related diseases.